IRA J GOTTLIEB
- Type
- Physician · Podiatric Medicine & Surgery Service Providers / Podiatrist
- Where
- PASADENA, MD
- NPI
- 1265430524
- Received
- $172,357 in 57 records, 2019 to 2025 ($24,622 general, $147,735 research)
- As principal investigator
- $4,599,087 of research payments to others in 70 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 1 | $124 |
| 2024 | General payment | 9 | $8,067 |
| 2023 | General payment | 10 | $2,222 |
| 2022 | General payment | 15 | $13,935 |
| 2021 | General payment | 1 | $125 |
| 2021 | Research payment | 1 | $13,668 |
| 2020 | Research payment | 5 | $48,381 |
| 2019 | General payment | 9 | $146 |
| 2019 | Research payment | 6 | $85,685 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Ipsen Innovation | 12 | $147,735 | 2019–2021 |
| Kowa Pharmaceuticals America, Inc. | 15 | $13,935 | 2022 |
| Hikma Pharmaceuticals USA | 9 | $8,067 | 2024 |
| Mylan Specialty L.P. | 10 | $2,222 | 2023 |
| Smith+Nephew, Inc. | 3 | $154 | 2019–2025 |
| ACADIA Pharmaceuticals Inc | 1 | $125 | 2021 |
| Melinta Therapeutics, LLC | 2 | $54 | 2019 |
| Glenmark Therapeutics Inc. | 1 | $14 | 2019 |
| Integra LifeSciences Corporation | 1 | $13 | 2019 |
| Supreme Orthopedic Systems, LLC | 1 | $12 | 2019 |
| Tactile Systems Technology Inc | 1 | $12 | 2019 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $9 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 12 | $147,735 |
| Consulting Fee | 7 | $11,528 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 1 | $6,900 |
| Travel and Lodging | 15 | $5,213 |
| Food and Beverage | 22 | $981 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-06-12 | Smith+Nephew, Inc. | $124 | Food and Beverage | In-kind items and services | STRAVIX PL Biological, Extra Cellular Matrix | 2025 | |
| 2024-12-11 | Hikma Pharmaceuticals USA | $6,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | COMBOGESIC IV Drug, Pain / Addiction | 2024 | |
| 2024-12-11 | Hikma Pharmaceuticals USA | $773 | Travel and Lodging | Cash or cash equivalent | COMBOGESIC IV Drug, Pain / Addiction | 2024 | |
| 2024-12-11 | Hikma Pharmaceuticals USA | $120 | Travel and Lodging | Cash or cash equivalent | COMBOGESIC IV Drug, Pain / Addiction | 2024 | |
| 2024-12-11 | Hikma Pharmaceuticals USA | $40 | Food and Beverage | Cash or cash equivalent | COMBOGESIC IV Drug, Pain / Addiction | 2024 | |
| 2024-12-11 | Hikma Pharmaceuticals USA | $19 | Food and Beverage | Cash or cash equivalent | COMBOGESIC IV Drug, Pain / Addiction | 2024 | |
| 2024-12-11 | Hikma Pharmaceuticals USA | $18 | Food and Beverage | Cash or cash equivalent | COMBOGESIC IV Drug, Pain / Addiction | 2024 | |
| 2024-12-11 | Hikma Pharmaceuticals USA | $17 | Food and Beverage | Cash or cash equivalent | COMBOGESIC IV Drug, Pain / Addiction | 2024 | |
| 2024-10-31 | Hikma Pharmaceuticals USA | $133 | Food and Beverage | In-kind items and services | COMBOGESIC IV Drug, Pain / Addiction | 2024 | |
| 2024-10-31 | Hikma Pharmaceuticals USA | $44 | Food and Beverage | In-kind items and services | COMBOGESIC IV Drug, Pain / Addiction | 2024 | |
| 2023-11-18 | Mylan Specialty L.P. | $163 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-11-17 | Mylan Specialty L.P. | $163 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-11-16 | Mylan Specialty L.P. | $777 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-11-16 | Mylan Specialty L.P. | $445 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-11-16 | Mylan Specialty L.P. | $163 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-11-16 | Mylan Specialty L.P. | $125 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-11-16 | Mylan Specialty L.P. | $115 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-11-16 | Mylan Specialty L.P. | $60 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-11-16 | Mylan Specialty L.P. | $45 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-11-15 | Mylan Specialty L.P. | $163 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2022-11-22 | Kowa Pharmaceuticals America, Inc. | $163 | Consulting Fee | Cash or cash equivalent | Seglentis Drug, Pain Management | 2022 | |
| 2022-11-22 | Kowa Pharmaceuticals America, Inc. | $45 | Consulting Fee | Cash or cash equivalent | Seglentis Drug, Pain Management | 2022 | |
| 2022-11-22 | Kowa Pharmaceuticals America, Inc. | $44 | Consulting Fee | Cash or cash equivalent | Seglentis Drug, Pain Management | 2022 | |
| 2022-10-06 | Kowa Pharmaceuticals America, Inc. | $2,200 | Consulting Fee | Cash or cash equivalent | Seglentis Drug, Pain Management | 2022 | |
| 2022-10-06 | Kowa Pharmaceuticals America, Inc. | $2,200 | Consulting Fee | Cash or cash equivalent | Seglentis Drug, Pain Management | 2022 | |
| 2022-09-07 | Kowa Pharmaceuticals America, Inc. | $47 | Food and Beverage | In-kind items and services | Seglentis Drug, Pain Management | 2022 | |
| 2022-09-07 | Kowa Pharmaceuticals America, Inc. | $32 | Food and Beverage | In-kind items and services | Seglentis Drug, Pain Management | 2022 | |
| 2022-09-06 | Kowa Pharmaceuticals America, Inc. | $1,165 | Travel and Lodging | In-kind items and services | Seglentis Drug, Pain Management | 2022 | |
| 2022-09-06 | Kowa Pharmaceuticals America, Inc. | $294 | Travel and Lodging | In-kind items and services | Seglentis Drug, Pain Management | 2022 | |
| 2022-05-05 | Kowa Pharmaceuticals America, Inc. | $5,225 | Consulting Fee | Cash or cash equivalent | Seglentis Drug, Pain Management | 2022 | |
| 2022-04-21 | Kowa Pharmaceuticals America, Inc. | $44 | Travel and Lodging | Cash or cash equivalent | Seglentis Drug, Pain Management | 2022 | |
| 2022-03-22 | Kowa Pharmaceuticals America, Inc. | $159 | Travel and Lodging | In-kind items and services | Seglentis Drug, Pain Management | 2022 | |
| 2022-03-21 | Kowa Pharmaceuticals America, Inc. | $497 | Travel and Lodging | In-kind items and services | Seglentis Drug, Pain Management | 2022 | |
| 2022-03-21 | Kowa Pharmaceuticals America, Inc. | $165 | Travel and Lodging | In-kind items and services | Seglentis Drug, Pain Management | 2022 | |
| 2022-01-27 | Kowa Pharmaceuticals America, Inc. | $1,650 | Consulting Fee | Cash or cash equivalent | Seglentis Drug, Pain Management | 2022 | |
| 2021-07-20 | ACADIA Pharmaceuticals Inc | $125 | Food and Beverage | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2021 | |
| 2021-01-29 | Ipsen Innovation | $13,668 | Research payment | Cash or cash equivalent | DYSPORT Drug, Neurology | A Multiple-dose, Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dysport for t | 2021 |
| 2020-05-08 | Ipsen Innovation | $8,507 | Research payment | Cash or cash equivalent | DYSPORT Drug, Neurology | A Multiple-dose, Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dysport for t | 2020 |
| 2020-04-13 | Ipsen Innovation | $4,637 | Research payment | Cash or cash equivalent | DYSPORT Drug, Neurology | A Multiple-dose, Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dysport for t | 2020 |
| 2020-03-16 | Ipsen Innovation | $9,188 | Research payment | Cash or cash equivalent | DYSPORT Drug, Neurology | A Multiple-dose, Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dysport for t | 2020 |
| 2020-02-18 | Ipsen Innovation | $20,256 | Research payment | Cash or cash equivalent | DYSPORT Drug, Neurology | A Multiple-dose, Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dysport for t | 2020 |
| 2020-01-13 | Ipsen Innovation | $5,791 | Research payment | Cash or cash equivalent | DYSPORT Drug, Neurology | A Multiple-dose, Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dysport for t | 2020 |
| 2019-12-16 | Ipsen Innovation | $11,457 | Research payment | Cash or cash equivalent | DYSPORT Drug, Neurology | A Multiple-dose, Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dysport for t | 2019 |
| 2019-11-04 | Ipsen Innovation | $15,450 | Research payment | Cash or cash equivalent | DYSPORT Drug, Neurology | A Multiple-dose, Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dysport for t | 2019 |
| 2019-10-14 | Ipsen Innovation | $8,132 | Research payment | Cash or cash equivalent | DYSPORT Drug, Neurology | A Multiple-dose, Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dysport for t | 2019 |
| 2019-10-03 | Melinta Therapeutics, LLC | $27 | Food and Beverage | In-kind items and services | Baxdela Drug, ANTIBIOTICS | 2019 | |
| 2019-09-17 | Ipsen Innovation | $16,623 | Research payment | Cash or cash equivalent | DYSPORT Drug, Neurology | A Multiple-dose, Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dysport for t | 2019 |
| 2019-08-22 | Glenmark Therapeutics Inc. | $14 | Food and Beverage | Cash or cash equivalent | Mupirocin Cream Drug, Topical Antibiotic | 2019 | |
| 2019-08-12 | Ipsen Innovation | $29,421 | Research payment | Cash or cash equivalent | DYSPORT Drug, Neurology | A Multiple-dose, Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dysport for t | 2019 |
| 2019-07-31 | Supreme Orthopedic Systems, LLC | $12 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-07-03 | Melinta Therapeutics, LLC | $27 | Food and Beverage | In-kind items and services | Baxdela Drug, ANTIBIOTICS | 2019 | |
| 2019-06-27 | Smith+Nephew, Inc. | $14 | Food and Beverage | In-kind items and services | PICO Single Use Negative Pressure Wound Therapy Device, Negative Pressure Wound Therapy | 2019 | |
| 2019-06-24 | Ipsen Innovation | $4,600 | Research payment | Cash or cash equivalent | DYSPORT Drug, Neurology | A Multiple-dose, Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dysport for t | 2019 |
| 2019-06-20 | Integra LifeSciences Corporation | $13 | Food and Beverage | In-kind items and services | OMNIGRAFT Device, RECON-SKIN AND WOUND | 2019 | |
| 2019-05-08 | Tactile Systems Technology Inc | $12 | Food and Beverage | In-kind items and services | FLEXITOUCH Device, PNEUMATIC COMPRESSOR | 2019 | |
| 2019-03-12 | Musculoskeletal Transplant Foundation Inc. | $9 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-02-28 | Smith+Nephew, Inc. | $15 | Food and Beverage | In-kind items and services | Santyl Drug, Pharma Product | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-11-30 | Organogenesis Inc. | CHESAPEAKE RESEARCH GROUP | $6,500 | PREPARE PuraPly AM/XT | 2025 |
| 2025-10-31 | Organogenesis Inc. | CHESAPEAKE RESEARCH GROUP | $13,000 | PREPARE PuraPly AM/XT | 2025 |
| 2025-09-30 | Organogenesis Inc. | CHESAPEAKE RESEARCH GROUP | $6,500 | PREPARE PuraPly AM/XT | 2025 |
| 2025-08-31 | Organogenesis Inc. | CHESAPEAKE RESEARCH GROUP | $13,000 | PREPARE PuraPly AM/XT | 2025 |
| 2025-08-21 | Tris Pharma Inc | Chesapeake Research Group, LLC | $68,249 | TRIPHA TRN-228-302_Bunion_P3 | 2025 |
| 2025-06-13 | Tris Pharma Inc | Chesapeake Research Group, LLC | $3,120 | TRIPHA TRN-228-302_Bunion_P3 | 2025 |
| 2025-06-09 | Tris Pharma Inc | Chesapeake Research Group, LLC | $5,726 | TRIPHA TRN-228-302_Bunion_P3 | 2025 |
| 2025-05-09 | Tris Pharma Inc | Chesapeake Research Group, LLC | $79,708 | TRIPHA TRN-228-302_Bunion_P3 | 2025 |
| 2025-05-09 | Tris Pharma Inc | Chesapeake Research Group, LLC | $10,000 | TRIPHA TRN-228-302_Bunion_P3 | 2025 |
| 2025-05-09 | Tris Pharma Inc | Chesapeake Research Group, LLC | $4,800 | TRIPHA TRN-228-302_Bunion_P3 | 2025 |
| 2025-04-30 | Organogenesis Inc. | CHESAPEAKE RESEARCH GROUP | $1,000 | PREPARE PuraPly AM/XT | 2025 |
| 2025-04-30 | Organogenesis Inc. | CHESAPEAKE RESEARCH GROUP | $5,000 | PREPARE PuraPly AM/XT | 2025 |
| 2025-04-30 | Organogenesis Inc. | CHESAPEAKE RESEARCH GROUP | $1,000 | PREPARE PuraPly AM/XT | 2025 |
| 2025-04-30 | Organogenesis Inc. | CHESAPEAKE RESEARCH GROUP | $9,500 | PREPARE PuraPly AM/XT | 2025 |
| 2025-04-25 | Tris Pharma Inc | Chesapeake Research Group, LLC | $5,000 | TRIPHA TRN-228-302_Bunion_P3 | 2025 |
| 2025-01-23 | Tris Pharma Inc | Chesapeake Research Group, LLC | $63,765 | TRIPHA TRN-228-302_Bunion_P3 | 2025 |
| 2025-01-23 | Tris Pharma Inc | Chesapeake Research Group, LLC | $329,239 | TRIPHA TRN-228-302_Bunion_P3 | 2025 |
| 2024-12-30 | Tris Pharma Inc | Chesapeake Research Group, LLC | $547,132 | TRIPHA TRN-228-302_Bunion_P3 | 2024 |
| 2024-10-17 | Tris Pharma Inc | Chesapeake Research Group, LLC | $131,188 | TRIPHA TRN-228-302_Bunion_P3 | 2024 |
| 2024-09-20 | Tris Pharma Inc | Chesapeake Research Group, LLC | $11,250 | TRIPHA TRN-228-302_Bunion_P3 | 2024 |
| 2024-09-20 | Tris Pharma Inc | Chesapeake Research Group, LLC | $68,632 | TRIPHA TRN-228-302_Bunion_P3 | 2024 |
| 2023-03-08 | VERTEX PHARMACEUTICALS INCORPORATED | CHESAPEAKE RESEARCH GROUP | $15,372 | A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of VX-548 for Acute Pai | 2023 |
| 2023-01-10 | VERTEX PHARMACEUTICALS INCORPORATED | CHESAPEAKE RESEARCH GROUP | $1 | A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of VX-548 | 2023 |
| 2022-12-14 | Endo Pharmaceuticals Inc. | CHESAPEAKE RESEARCH GROUP LLC | $1,652 | A Multi-Center, Open-Label, Extension Study to Evaluate the Long-Term Safety, Efficacy, and Durability of EN3835 in the | 2022 |
| 2022-12-14 | Endo Pharmaceuticals Inc. | CHESAPEAKE RESEARCH GROUP LLC | $3,475 | A Phase 1, Single Blind, Randomized, Placebo Controlled Dose Escalation Study to Assess the Safety, Effectiveness and To | 2022 |
| 2022-11-16 | Endo Pharmaceuticals Inc. | CHESAPEAKE RESEARCH GROUP LLC | $1,652 | A Multi-Center, Open-Label, Extension Study to Evaluate the Long-Term Safety, Efficacy, and Durability of EN3835 in the | 2022 |
| 2022-10-19 | Endo Pharmaceuticals Inc. | CHESAPEAKE RESEARCH GROUP LLC | $3,206 | A Multi-Center, Open-Label, Extension Study to Evaluate the Long-Term Safety, Efficacy, and Durability of EN3835 in the | 2022 |
| 2022-10-19 | Endo Pharmaceuticals Inc. | CHESAPEAKE RESEARCH GROUP LLC | $2,965 | A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacok | 2022 |
| 2022-10-05 | Endo Pharmaceuticals Inc. | CHESAPEAKE RESEARCH GROUP LLC | $4,500 | A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacok | 2022 |
| 2022-09-26 | ACADIA Pharmaceuticals Inc | CHESAPEAKE RESEARCH GROUP LLC | $10,158 | ACP-044-004 | 2022 |
| 2022-09-21 | Endo Pharmaceuticals Inc. | CHESAPEAKE RESEARCH GROUP LLC | $1,554 | A Multi-Center, Open-Label, Extension Study to Evaluate the Long-Term Safety, Efficacy, and Durability of EN3835 in the | 2022 |
| 2022-09-21 | Endo Pharmaceuticals Inc. | CHESAPEAKE RESEARCH GROUP LLC | $2,407 | A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacok | 2022 |
| 2022-09-21 | Endo Pharmaceuticals Inc. | CHESAPEAKE RESEARCH GROUP LLC | $8,083 | A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacok | 2022 |
| 2022-09-21 | Endo Pharmaceuticals Inc. | CHESAPEAKE RESEARCH GROUP LLC | $1,554 | A Multi-Center, Open-Label, Extension Study to Evaluate the Long-Term Safety, Efficacy, and Durability of EN3835 in the | 2022 |
| 2022-08-24 | Endo Pharmaceuticals Inc. | CHESAPEAKE RESEARCH GROUP LLC | $5,866 | A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacok | 2022 |
| 2022-08-24 | Endo Pharmaceuticals Inc. | CHESAPEAKE RESEARCH GROUP LLC | $3,108 | A Multi-Center, Open-Label, Extension Study to Evaluate the Long-Term Safety, Efficacy, and Durability of EN3835 in the | 2022 |
| 2022-07-12 | Endo Pharmaceuticals Inc. | CHESAPEAKE RESEARCH GROUP LLC | $10,236 | A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacok | 2022 |
| 2022-07-05 | ACADIA Pharmaceuticals Inc | CHESAPEAKE RESEARCH GROUP LLC | $1,044 | ACP-044-004 | 2022 |
| 2022-06-20 | ACADIA Pharmaceuticals Inc | CHESAPEAKE RESEARCH GROUP LLC | $11,977 | ACP-044-004 | 2022 |
| 2022-06-20 | ACADIA Pharmaceuticals Inc | CHESAPEAKE RESEARCH GROUP LLC | $6,028 | ACP-044-004 | 2022 |
| 2022-06-20 | ACADIA Pharmaceuticals Inc | CHESAPEAKE RESEARCH GROUP LLC | $35,740 | ACP-044-004 | 2022 |
| 2022-06-20 | ACADIA Pharmaceuticals Inc | CHESAPEAKE RESEARCH GROUP LLC | $2,590 | ACP-044-004 | 2022 |
| 2022-06-20 | ACADIA Pharmaceuticals Inc | CHESAPEAKE RESEARCH GROUP LLC | $31,961 | ACP-044-004 | 2022 |
| 2022-06-20 | ACADIA Pharmaceuticals Inc | CHESAPEAKE RESEARCH GROUP LLC | $26,591 | ACP-044-004 | 2022 |
| 2022-06-14 | Endo Pharmaceuticals Inc. | CHESAPEAKE RESEARCH GROUP LLC | $3,757 | A Multi-Center, Open-Label, Extension Study to Evaluate the Long-Term Safety, Efficacy, and Durability of EN3835 in the | 2022 |
| 2022-06-14 | Endo Pharmaceuticals Inc. | CHESAPEAKE RESEARCH GROUP LLC | $4,878 | A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacok | 2022 |
| 2022-06-07 | ACADIA Pharmaceuticals Inc | CHESAPEAKE RESEARCH GROUP LLC | $10,753 | ACP-044-004 | 2022 |
| 2022-05-17 | Endo Pharmaceuticals Inc. | CHESAPEAKE RESEARCH GROUP LLC | $4,406 | A Multi-Center, Open-Label, Extension Study to Evaluate the Long-Term Safety, Efficacy, and Durability of EN3835 in the | 2022 |
| 2022-05-17 | Endo Pharmaceuticals Inc. | CHESAPEAKE RESEARCH GROUP LLC | $15,255 | A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacok | 2022 |
| 2022-05-05 | ACADIA Pharmaceuticals Inc | CHESAPEAKE RESEARCH GROUP LLC | $20,555 | ACP-044-004 | 2022 |
| 2022-04-20 | ACADIA Pharmaceuticals Inc | CHESAPEAKE RESEARCH GROUP LLC | $1,234 | ACP-044-004 | 2022 |
| 2022-04-12 | Endo Pharmaceuticals Inc. | CHESAPEAKE RESEARCH GROUP LLC | $16,709 | A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacok | 2022 |
| 2022-04-12 | Endo Pharmaceuticals Inc. | CHESAPEAKE RESEARCH GROUP LLC | $3,675 | A Multi-Center, Open-Label, Extension Study to Evaluate the Long-Term Safety, Efficacy, and Durability of EN3835 in the | 2022 |
| 2022-04-06 | ACADIA Pharmaceuticals Inc | CHESAPEAKE RESEARCH GROUP LLC | $183,761 | ACP-044-004 | 2022 |
| 2022-03-15 | Endo Pharmaceuticals Inc. | CHESAPEAKE RESEARCH GROUP LLC | $5,118 | A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacok | 2022 |
| 2022-02-04 | VERTEX PHARMACEUTICALS INCORPORATED | CHESAPEAKE RESEARCH GROUP | $605,907 | A Phase 2 Randomized Double - blind Placebo - controlled Study Evaluating the Efficacy and Safety of VX-548 for Acute Pa | 2022 |
| 2022-02-04 | ACADIA Pharmaceuticals Inc | CHESAPEAKE RESEARCH GROUP LLC | $41,293 | ACP-044-004 | 2022 |
| 2022-01-18 | Endo Pharmaceuticals Inc. | CHESAPEAKE RESEARCH GROUP LLC | $3,675 | A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacok | 2022 |
| 2022-01-11 | VERTEX PHARMACEUTICALS INCORPORATED | CHESAPEAKE RESEARCH GROUP | $717,079 | A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of VX-548 | 2022 |
| 2021-12-20 | ACADIA Pharmaceuticals Inc | CHESAPEAKE RESEARCH GROUP LLC | $45,636 | ACP-044-004 | 2021 |
| 2021-12-07 | ACADIA Pharmaceuticals Inc | CHESAPEAKE RESEARCH GROUP LLC | $55,491 | ACP-044-004 | 2021 |
| 2021-11-19 | ACADIA Pharmaceuticals Inc | CHESAPEAKE RESEARCH GROUP LLC | $58,272 | ACP-044-004 | 2021 |
| 2021-11-19 | ACADIA Pharmaceuticals Inc | CHESAPEAKE RESEARCH GROUP LLC | $67,986 | ACP-044-004 | 2021 |
| 2021-11-19 | ACADIA Pharmaceuticals Inc | CHESAPEAKE RESEARCH GROUP LLC | $1,872 | ACP-044-004 | 2021 |
| 2021-11-19 | ACADIA Pharmaceuticals Inc | CHESAPEAKE RESEARCH GROUP LLC | $11,109 | ACP-044-004 | 2021 |
| 2021-10-29 | VERTEX PHARMACEUTICALS INCORPORATED | CHESAPEAKE RESEARCH GROUP | $282,222 | A Phase 2 randomized double blind placebo controlled study evaluating the efficacy and safety of VX-548 for acute pain a | 2021 |
| 2021-10-13 | ACADIA Pharmaceuticals Inc | CHESAPEAKE RESEARCH GROUP LLC | $72,030 | ACP-044-004 | 2021 |
| 2021-10-06 | ACADIA Pharmaceuticals Inc | CHESAPEAKE RESEARCH GROUP LLC | $21,996 | ACP-044-004 | 2021 |
| 2021-08-09 | VERTEX PHARMACEUTICALS INCORPORATED | CHESAPEAKE RESEARCH GROUP | $137,086 | A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of VX-548 | 2021 |
| 2019-01-01 | VERTEX PHARMACEUTICALS INCORPORATED | CHESAPEAKE RESEARCH GROUP | $632,286 | A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Pasadena, MD, county Anne Arundel County, MD, state Maryland; placed by its city name.
| Measure | Place (city or town) Pasadena, MD | County Anne Arundel County, MD | State Maryland |
|---|---|---|---|
| Population B01003 | 34,309 | 598,166 | 6,206,011 |
| Population, 2020 census P1 | 32,979 | 588,261 | 6,177,224 |
| Median age B01002 | 35.9 | 39.0 | 39.4 |
| Under 18 B01001 | 20.8% | 22.4% | 22.2% |
| 65 and over B01001 | 11.8% | 15.9% | 16.7% |
| Households B11001 | 12,744 | 224,748 | 2,362,928 |
| Foreign born B05002 | 7.1% | 10.0% | 16.6% |
| Median household income B19013 | $129,727 | $124,911 | $103,678 |
| Median family income B19113 | $138,947 | $147,004 | $127,817 |
| Per capita income B19301 | $56,178 | $59,733 | $52,979 |
| Poverty rate B17001 | 5.7% | 5.6% | 9.4% |
| Unemployment rate B23025 | 1.6% | 3.7% | 4.9% |
| Civilian labor force B23025 | 20,167 | 318,663 | 3,313,651 |
| Mean commute (minutes) B08013 | 31.6 | 28.9 | 31.1 |
| Bachelor's degree or higher B15003 | 38.2% | 45.8% | 43.4% |
| Housing units B25001 | 12,978 | 236,262 | 2,560,784 |
| Owner-occupied B25003 | 83.7% | 75.1% | 67.6% |
| Renters B25003 | 16.3% | 24.9% | 32.4% |
| Median home value B25077 | $423,400 | $467,900 | $419,900 |
| Median gross rent B25064 | $2,393 | $2,071 | $1,705 |
| White, not Hispanic B03002 | 66.6% | 61.7% | 46.6% |
| Black B03002 | 17.3% | 17.6% | 28.9% |
| Hispanic or Latino B03002 | 7.3% | 10.5% | 12.5% |
| Asian B03002 | 3.2% | 4.2% | 6.5% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Pasadena, MD.
Comments